id,smiles,ACTIVITY2,ACTIVITY1,deephit,pred-hERG,pred-hERG-score,score,Unnamed: 8,Unnamed: 9,Unnamed: 10,st_smiles
acalabrutinib,CC#CC(=O)N1CCCC1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,0,0,1,1,0.5,0.5,hERG blocker,acalabrutinib,1,CC#CC(=O)N1CCCC1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12
aclidinium bromide,O=C(OC1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1,0,0,1,1,0.6,0.6,hERG blocker,aclidinium bromide,1,O=C(OC1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1
afatinib,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC1CCOC1,0,1,1,1,0.5,0.5,hERG blocker,afatinib,1,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC1CCOC1
alogliptin,Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O,0,0,1,0,0.6,0.4,hERG blocker,alogliptin,1,Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O
amifampridine,Nc1ccncc1N,0,0,0,0,0.7,0.3,hERG non-blocker,amifampridine,1,Nc1ccncc1N
apalutamide,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,0,1,0,0,0.5,0.5,hERG non-blocker,apalutamide,1,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F
apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,0,0,0,0,0.5,0.5,hERG non-blocker,apixaban,1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1
apremilast,CCOc1cc(C(CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,0,0,0,0,0.6,0.4,hERG non-blocker,apremilast,1,CCOc1cc(C(CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC
aripiprazole lauroxil,CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21,1,1,1,1,0.7,0.7,hERG blocker,aripiprazole lauroxil,1,CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21
avanafil,COc1ccc(CNc2nc(N3CCCC3CO)ncc2C(=O)NCc2ncccn2)cc1Cl,0,0,0,1,0.5,0.5,hERG non-blocker,avanafil,1,COc1ccc(CNc2nc(N3CCCC3CO)ncc2C(=O)NCc2ncccn2)cc1Cl
avatrombopag,O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1,0,1,0,0,0.5,0.5,hERG non-blocker,avatrombopag,1,O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1
avibactam,NC(=O)C1CCC2CN1C(=O)N2OS(=O)(=O)O,0,0,0,0,0.7,0.3,hERG non-blocker,avibactam,1,NC(=O)C1CCC2CN1C(=O)N2OS(=O)(=O)O
axitinib,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,0,0,0,1,0.6,0.6,hERG non-blocker,axitinib,1,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
baloxavir marboxil,COC(=O)OCOc1c2n(ccc1=O)N(C1c3ccccc3SCc3c1ccc(F)c3F)C1COCCN1C2=O,0,0,0,1,0.5,0.5,hERG non-blocker,baloxavir marboxil,1,COC(=O)OCOc1c2n(ccc1=O)N(C1c3ccccc3SCc3c1ccc(F)c3F)C1COCCN1C2=O
baricitinib,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,0,0,0,0,0.5,0.5,hERG non-blocker,baricitinib,1,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
bazedoxifene,Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,0,1,1,1,0.7,0.7,hERG blocker,bazedoxifene,1,Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12
bedaquiline,COc1nc2ccc(Br)cc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12,1,1,1,1,0.6,0.6,hERG blocker,bedaquiline,1,COc1nc2ccc(Br)cc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12
benznidazole,O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1,0,0,0,0,0.8,0.2,hERG non-blocker,benznidazole,1,O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1
bictegravir,O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1C3CCC(C3)OC1C2,0,0,0,0,0.5,0.5,hERG non-blocker,bictegravir,1,O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1C3CCC(C3)OC1C2
binimetinib,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,0,0,0,0,0.6,0.4,hERG non-blocker,binimetinib,1,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21
bosutinib,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,1,1,1,1,0.7,0.7,hERG blocker,bosutinib,1,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
brexpiprazole,O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1,1,1,1,1,0.7,0.7,hERG blocker,brexpiprazole,1,O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1
brigatinib,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,0,0,1,1,0.6,0.6,hERG blocker,brigatinib,1,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1
brivaracetam,CCCC1CC(=O)N(C(CC)C(N)=O)C1,0,0,0,0,0.7,0.3,hERG non-blocker,brivaracetam,1,CCCC1CC(=O)N(C(CC)C(N)=O)C1
cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,0,0,1,0,0.6,0.4,hERG blocker,cabozantinib,1,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
canagliflozin,Cc1ccc(C2OC(CO)C(O)C(O)C2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,0,0,1,0,0.5,0.5,hERG blocker,canagliflozin,1,Cc1ccc(C2OC(CO)C(O)C(O)C2O)cc1Cc1ccc(-c2ccc(F)cc2)s1
cangrelor,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2C1OC(COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)C(O)C1O,0,0,0,1,0.6,0.6,hERG non-blocker,cangrelor,1,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2C1OC(COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)C(O)C1O
cannabidiol,C=C(C)C1CCC(C)=CC1c1c(O)cc(CCCCC)cc1O,0,1,1,1,0.7,0.7,hERG blocker,cannabidiol,1,C=C(C)C1CCC(C)=CC1c1c(O)cc(CCCCC)cc1O
carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,0,1,0,1,0.6,0.6,hERG non-blocker,carfilzomib,1,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1
ceftolozane,Cn1c(N)c(NC(=O)NCCN)c[n+]1CC1=C(C(=O)[O-])N2C(=O)C(NC(=O)/C(=N\OC(C)(C)C(=O)O)c3nsc(N)n3)C2SC1,0,0,0,1,0.5,0.5,hERG non-blocker,ceftolozane,1,Cn1c(N)c(NC(=O)NCCN)c[n+]1CC1=C(C(=O)[O-])N2C(=O)C(NC(=O)/C(=N\OC(C)(C)C(=O)O)c3nsc(N)n3)C2SC1
ceritinib,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,1,1,0,1,0.8,0.8,hERG non-blocker,ceritinib,1,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1
cholic acid,CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C,0,0,0,0,0.6,0.4,hERG non-blocker,cholic acid,1,CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C
cobicistat,CC(C)c1nc(CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0,1,0,1,0.5,0.5,hERG non-blocker,cobicistat,1,CC(C)c1nc(CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
cobimetinib,O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)(C2CCCCN2)C1,1,1,1,1,0.5,0.5,hERG blocker,cobimetinib,1,O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)(C2CCCCN2)C1
copanlisib,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,0,0,0,1,0.5,0.5,hERG non-blocker,copanlisib,1,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21
crisaborole,N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1,0,0,1,1,0.6,0.6,hERG blocker,crisaborole,1,N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1
dabrafenib,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,0,0,1,1,0.6,0.6,hERG blocker,dabrafenib,1,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
dacomitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,0,1,1,0,0.5,0.5,hERG blocker,dacomitinib,1,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1
dapagliflozin,CCOc1ccc(Cc2cc(C3OC(CO)C(O)C(O)C3O)ccc2Cl)cc1,0,0,1,1,0.6,0.6,hERG blocker,dapagliflozin,1,CCOc1ccc(Cc2cc(C3OC(CO)C(O)C(O)C3O)ccc2Cl)cc1
dasabuvir,COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C,0,0,0,1,0.6,0.6,hERG non-blocker,dasabuvir,1,COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C
deflazacort,CC(=O)OCC(=O)C12N=C(C)OC1CC1C3CCC4=CC(=O)C=CC4(C)C3C(O)CC12C,0,0,0,0,0.5,0.5,hERG non-blocker,deflazacort,1,CC(=O)OCC(=O)C12N=C(C)OC1CC1C3CCC4=CC(=O)C=CC4(C)C3C(O)CC12C
delafloxacin,Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(O)C4)c(Cl)c32)c(F)cc1F,0,0,0,0,0.6,0.4,hERG non-blocker,delafloxacin,1,Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(O)C4)c(Cl)c32)c(F)cc1F
deoxycholic acid,CC(CCC(=O)O)C1CCC2C3CCC4CC(O)CCC4(C)C3CC(O)C12C,0,0,0,0,0.5,0.5,hERG non-blocker,deoxycholic acid,1,CC(CCC(=O)O)C1CCC2C3CCC4CC(O)CCC4(C)C3CC(O)C12C
deutetrabenazine,[2H]C([2H])([2H])Oc1cc2c(cc1OC([2H])([2H])[2H])C1CC(=O)C(CC(C)C)CN1CC2,0,0,0,0,0.5,0.5,hERG non-blocker,deutetrabenazine,1,[2H]C([2H])([2H])Oc1cc2c(cc1OC([2H])([2H])[2H])C1CC(=O)C(CC(C)C)CN1CC2
dimethyl fumarate,COC(=O)/C=C/C(=O)OC,0,0,0,0,0.9,0.1,hERG non-blocker,dimethyl fumarate,1,COC(=O)/C=C/C(=O)OC
dolutegravir,CC1CCOC2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0,0,0,0,0.6,0.4,hERG non-blocker,dolutegravir,1,CC1CCOC2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
doravirine,Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O,0,0,0,1,0.5,0.5,hERG non-blocker,doravirine,1,Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O
droxidopa,NC(C(=O)O)C(O)c1ccc(O)c(O)c1,0,0,0,0,0.7,0.3,hERG non-blocker,droxidopa,1,NC(C(=O)O)C(O)c1ccc(O)c(O)c1
duvelisib,CC(Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,1,0,1,0.6,0.6,hERG non-blocker,duvelisib,1,CC(Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1
edaravone,CC1=NN(c2ccccc2)C(=O)C1,0,0,0,1,0.6,0.6,hERG non-blocker,edaravone,1,CC1=NN(c2ccccc2)C(=O)C1
edoxaban,CN1CCc2nc(C(=O)NC3CC(C(=O)N(C)C)CCC3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,0,0,0,1,0.5,0.5,hERG non-blocker,edoxaban,1,CN1CCc2nc(C(=O)NC3CC(C(=O)N(C)C)CCC3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1
efinaconazole,C=C1CCN(C(C)C(O)(Cn2cncn2)c2ccc(F)cc2F)CC1,0,0,0,0,0.7,0.3,hERG non-blocker,efinaconazole,1,C=C1CCN(C(C)C(O)(Cn2cncn2)c2ccc(F)cc2F)CC1
elagolix sodium,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(NCCCC(=O)O)c3ccccc3)c2=O)c1F,0,0,0,1,0.6,0.6,hERG non-blocker,elagolix sodium,1,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(NCCCC(=O)O)c3ccccc3)c2=O)c1F
eliglustat,CCCCCCCC(=O)NC(CN1CCCC1)C(O)c1ccc2c(c1)OCCO2,1,1,0,0,0.5,0.5,hERG non-blocker,eliglustat,1,CCCCCCCC(=O)NC(CN1CCCC1)C(O)c1ccc2c(c1)OCCO2
eluxadoline,COc1ccc(CN(C(=O)C(N)Cc2c(C)cc(C(N)=O)cc2C)C(C)c2nc(-c3ccccc3)c[nH]2)cc1C(=O)O,0,0,0,1,0.5,0.5,hERG non-blocker,eluxadoline,1,COc1ccc(CN(C(=O)C(N)Cc2c(C)cc(C(N)=O)cc2C)C(C)c2nc(-c3ccccc3)c[nH]2)cc1C(=O)O
elvitegravir,COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2C(CO)C(C)C,0,0,0,0,0.6,0.4,hERG non-blocker,elvitegravir,1,COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2C(CO)C(C)C
empagliflozin,OCC1OC(c2ccc(Cl)c(Cc3ccc(OC4CCOC4)cc3)c2)C(O)C(O)C1O,0,0,0,1,0.6,0.6,hERG non-blocker,empagliflozin,1,OCC1OC(c2ccc(Cl)c(Cc3ccc(OC4CCOC4)cc3)c2)C(O)C(O)C1O
enasidenib,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,0,1,0,1,0.6,0.6,hERG non-blocker,enasidenib,1,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1
encorafenib,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,0,0,1,1,0.5,0.5,hERG blocker,encorafenib,1,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,0,0,0,1,0.5,0.5,hERG non-blocker,enzalutamide,1,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F
eravacycline,CN(C)C1C(O)=C(C(N)=O)C(=O)C2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4CC3CC12,0,0,0,0,0.5,0.5,hERG non-blocker,eravacycline,1,CN(C)C1C(O)=C(C(N)=O)C(=O)C2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4CC3CC12
ertugliflozin,CCOc1ccc(Cc2cc(C34OCC(CO)(O3)C(O)C(O)C4O)ccc2Cl)cc1,0,0,0,1,0.6,0.6,hERG non-blocker,ertugliflozin,1,CCOc1ccc(Cc2cc(C34OCC(CO)(O3)C(O)C(O)C4O)ccc2Cl)cc1
eslicarbazepine acetate,CC(=O)OC1Cc2ccccc2N(C(N)=O)c2ccccc21,0,0,0,1,0.5,0.5,hERG non-blocker,eslicarbazepine acetate,1,CC(=O)OC1Cc2ccccc2N(C(N)=O)c2ccccc21
flibanserin,O=c1[nH]c2ccccc2n1CCN1CCN(c2cccc(C(F)(F)F)c2)CC1,0,0,1,1,0.7,0.7,hERG blocker,flibanserin,1,O=c1[nH]c2ccccc2n1CCN1CCN(c2cccc(C(F)(F)F)c2)CC1
Florbetapir F 18,CNc1ccc(/C=C/c2ccc(OCCOCCOCC[18F])nc2)cc1,0,0,1,0,0.5,0.5,hERG blocker,Florbetapir F 18,1,CNc1ccc(/C=C/c2ccc(OCCOCCOCC[18F])nc2)cc1
fluciclovine F 18,NC1(C(=O)O)CC([18F])C1,0,0,0,0,1,0,hERG non-blocker,fluciclovine F 18,1,NC1(C(=O)O)CC([18F])C1
flutemetamol F-18,CNc1ccc(-c2nc3ccc(O)cc3s2)cc1[18F],0,0,1,0,0.6,0.4,hERG blocker,flutemetamol F-18,1,CNc1ccc(-c2nc3ccc(O)cc3s2)cc1[18F]
fosnetupitant,Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,0,0,1,1,0.5,0.5,hERG blocker,fosnetupitant,1,Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
gadoterate meglumine,O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1,0,0,0,0,0.7,0.3,hERG non-blocker,gadoterate meglumine,1,O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1
gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,0,0,1,0,0.5,0.5,hERG blocker,gilteritinib,1,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
glasdegib,CN1CCC(NC(=O)Nc2ccc(C#N)cc2)CC1c1nc2ccccc2[nH]1,0,1,1,0,0.5,0.5,hERG blocker,glasdegib,1,CN1CCC(NC(=O)Nc2ccc(C#N)cc2)CC1c1nc2ccccc2[nH]1
ibrutinib,C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,1,1,1,1,0.6,0.6,hERG blocker,ibrutinib,1,C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1
idelalisib,CCC(Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,0,0,1,0.5,0.5,hERG non-blocker,idelalisib,1,CCC(Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1
ingenol mebutate,C/C=C(/C)C(=O)OC1C(C)=CC23C(=O)C(C=C(CO)C(O)C12O)C1C(CC3C)C1(C)C,0,0,0,0,0.6,0.4,hERG non-blocker,ingenol mebutate,1,C/C=C(/C)C(=O)OC1C(C)=CC23C(=O)C(C=C(CO)C(O)C12O)C1C(CC3C)C1(C)C
ivabradine,COc1cc2c(cc1OC)CC(=O)N(CCCN(C)CC1Cc3cc(OC)c(OC)cc31)CC2,0,0,1,1,0.6,0.6,hERG blocker,ivabradine,1,COc1cc2c(cc1OC)CC(=O)N(CCCN(C)CC1Cc3cc(OC)c(OC)cc31)CC2
ivosidenib,N#Cc1ccnc(N2C(=O)CCC2C(=O)N(c2cncc(F)c2)C(C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,0,0,0,1,0.6,0.6,hERG non-blocker,ivosidenib,1,N#Cc1ccnc(N2C(=O)CCC2C(=O)N(c2cncc(F)c2)C(C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
ixazomib,CC(C)CC(NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,0,0,0,0,0.6,0.4,hERG non-blocker,ixazomib,1,CC(C)CC(NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O
larotrectinib,O=C(Nc1cnn2ccc(N3CCCC3c3cc(F)ccc3F)nc12)N1CCC(O)C1,0,0,0,0,0.5,0.5,hERG non-blocker,larotrectinib,1,O=C(Nc1cnn2ccc(N3CCCC3c3cc(F)ccc3F)nc12)N1CCC(O)C1
latanoprostene bunod,O=C(CCC/C=C\CC1C(O)CC(O)C1CCC(O)CCc1ccccc1)OCCCCO[N+](=O)[O-],0,0,1,1,0.6,0.6,hERG blocker,latanoprostene bunod,1,O=C(CCC/C=C\CC1C(O)CC(O)C1CCC(O)CCc1ccccc1)OCCCCO[N+](=O)[O-]
ledipasvir,COC(=O)NC(C(=O)N1CC2(CC2)CC1c1ncc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5nc(C6C7CCC(C7)N6C(=O)C(NC(=O)OC)C(C)C)[nH]c5c4)ccc2-3)[nH]1)C(C)C,0,0,0,1,0.5,0.5,hERG non-blocker,ledipasvir,1,COC(=O)NC(C(=O)N1CC2(CC2)CC1c1ncc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5nc(C6C7CCC(C7)N6C(=O)C(NC(=O)OC)C(C)C)[nH]c5c4)ccc2-3)[nH]1)C(C)C
lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,0,0,1,0,0.5,0.5,hERG blocker,lenvatinib,1,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
letermovir,COc1cccc(N2CCN(C3=Nc4c(F)cccc4C(CC(=O)O)N3c3cc(C(F)(F)F)ccc3OC)CC2)c1,0,0,1,1,0.6,0.6,hERG blocker,letermovir,1,COc1cccc(N2CCN(C3=Nc4c(F)cccc4C(CC(=O)O)N3c3cc(C(F)(F)F)ccc3OC)CC2)c1
lofexidine hydrochloride,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1,0,0,1,1,0.7,0.7,hERG blocker,lofexidine hydrochloride,1,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1
lomitapide,O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c3ccccc32)CC1)c1ccccc1-c1ccc(C(F)(F)F)cc1,0,1,1,1,0.6,0.6,hERG blocker,lomitapide,1,O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c3ccccc32)CC1)c1ccccc1-c1ccc(C(F)(F)F)cc1
lorcaserin hydrochloride,CC1CNCCc2ccc(Cl)cc21,0,0,0,1,0.8,0.8,hERG non-blocker,lorcaserin hydrochloride,1,CC1CNCCc2ccc(Cl)cc21
luliconazole,N#C/C(=C1/SCC(c2ccc(Cl)cc2Cl)S1)n1ccnc1,0,1,0,0,0.5,0.5,hERG non-blocker,luliconazole,1,N#C/C(=C1/SCC(c2ccc(Cl)cc2Cl)S1)n1ccnc1
lumacaftor,Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1,0,0,0,0,0.6,0.4,hERG non-blocker,lumacaftor,1,Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1
lusutrombopag,CCCCCCOC(C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC,0,1,1,1,0.6,0.6,hERG blocker,lusutrombopag,1,CCCCCCOC(C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC
macimorelin,CC(C)(N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(Cc1c[nH]c2ccccc12)NC=O,0,0,1,0,0.5,0.5,hERG blocker,macimorelin,1,CC(C)(N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(Cc1c[nH]c2ccccc12)NC=O
macitentan,CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,0,0,1,1,0.6,0.6,hERG blocker,macitentan,1,CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1
midostaurin,COC1C(N(C)C(=O)c2ccccc2)CC2OC1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,0,0,1,0,0.5,0.5,hERG blocker,midostaurin,1,COC1C(N(C)C(=O)c2ccccc2)CC2OC1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
migalastat,OCC1NCC(O)C(O)C1O,0,0,0,0,0.6,0.4,hERG non-blocker,migalastat,1,OCC1NCC(O)C(O)C1O
mirabegron,Nc1nc(CC(=O)Nc2ccc(CCNCC(O)c3ccccc3)cc2)cs1,0,0,1,1,0.6,0.6,hERG blocker,mirabegron,1,Nc1nc(CC(=O)Nc2ccc(CCNCC(O)c3ccccc3)cc2)cs1
moxidectin,CO/N=C1\CC2(CC3CC(C/C=C(/C)CC(C)/C=C\C=C4\COC5C(O)C(C)=CC(C(=O)O3)C45O)O2)OC(/C(C)=C/C(C)C)C1C,0,0,0,1,0.5,0.5,hERG non-blocker,moxidectin,1,CO/N=C1\CC2(CC3CC(C/C=C(/C)CC(C)/C=C\C=C4\COC5C(O)C(C)=CC(C(=O)O3)C45O)O2)OC(/C(C)=C/C(C)C)C1C
naldemedine,CC(C)(NC(=O)C1=C(O)C2Oc3c(O)ccc4c3C23CCN(CC2CC2)C(C4)C3(O)C1)c1nc(-c2ccccc2)no1,0,0,1,1,0.5,0.5,hERG blocker,naldemedine,1,CC(C)(NC(=O)C1=C(O)C2Oc3c(O)ccc4c3C23CCN(CC2CC2)C(C4)C3(O)C1)c1nc(-c2ccccc2)no1
naloxegol,C=CCN1CCC23c4c5ccc(O)c4OC2C(OCCOCCOCCOCCOCCOCCOCCOC)CCC3(O)C1C5,0,0,1,1,0.6,0.6,hERG blocker,naloxegol,1,C=CCN1CCC23c4c5ccc(O)c4OC2C(OCCOCCOCCOCCOCCOCCOCCOC)CCC3(O)C1C5
neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,0,1,1,1,0.5,0.5,hERG blocker,neratinib,1,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C
netarsudil,Cc1ccc(C(=O)OCc2ccc(C(CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1,1,1,1,1,0.5,0.5,hERG blocker,netarsudil,1,Cc1ccc(C(=O)OCc2ccc(C(CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1
netupitant,Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,1,1,1,1,0.5,0.5,hERG blocker,netupitant,1,Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
niraparib,NC(=O)c1cccc2cn(-c3ccc(C4CCCNC4)cc3)nc12,0,1,1,1,0.6,0.6,hERG blocker,niraparib,1,NC(=O)c1cccc2cn(-c3ccc(C4CCCNC4)cc3)nc12
obeticholic acid,CCC1C(O)C2C3CCC(C(C)CCC(=O)O)C3(C)CCC2C2(C)CCC(O)CC12,0,0,0,1,0.5,0.5,hERG non-blocker,obeticholic acid,1,CCC1C(O)C2C3CCC(C(C)CCC(=O)O)C3(C)CCC2C2(C)CCC(O)CC12
olaparib,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,0,0,0,0,0.5,0.5,hERG non-blocker,olaparib,1,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1
olodaterol,COc1ccc(CC(C)(C)NCC(O)c2cc(O)cc3c2OCC(=O)N3)cc1,0,0,1,1,0.6,0.6,hERG blocker,olodaterol,1,COc1ccc(CC(C)(C)NCC(O)c2cc(O)cc3c2OCC(=O)N3)cc1
omacetaxine mepesuccinate,COC(=O)CC(O)(CCCC(C)(C)O)C(=O)OC1C(OC)=CC23CCCN2CCc2cc4c(cc2C13)OCO4,0,0,0,0,0.5,0.5,hERG non-blocker,omacetaxine mepesuccinate,1,COC(=O)CC(O)(CCCC(C)(C)O)C(=O)OC1C(OC)=CC23CCCN2CCc2cc4c(cc2C13)OCO4
omadacycline,CN(C)c1cc(CNCC(C)(C)C)c(O)c2c1CC1CC3C(N(C)C)C(O)=C(C(N)=O)C(=O)C3(O)C(O)=C1C2=O,0,0,0,0,0.6,0.4,hERG non-blocker,omadacycline,1,CN(C)c1cc(CNCC(C)(C)C)c(O)c2c1CC1CC3C(N(C)C)C(O)=C(C(N)=O)C(=O)C3(O)C(O)=C1C2=O
ombitasvir,COC(=O)NC(C(=O)N1CCCC1C(=O)Nc1ccc(C2CCC(c3ccc(NC(=O)C4CCCN4C(=O)C(NC(=O)OC)C(C)C)cc3)N2c2ccc(C(C)(C)C)cc2)cc1)C(C)C,0,0,0,1,0.5,0.5,hERG non-blocker,ombitasvir,1,COC(=O)NC(C(=O)N1CCCC1C(=O)Nc1ccc(C2CCC(c3ccc(NC(=O)C4CCCN4C(=O)C(NC(=O)OC)C(C)C)cc3)N2c2ccc(C(C)(C)C)cc2)cc1)C(C)C
osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,1,1,0,0,0.9,0.1,hERG non-blocker,osimertinib,1,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C
ospemifene,OCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,0,1,1,1,0.6,0.6,hERG blocker,ospemifene,1,OCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1
ozenoxacin,CNc1ncc(-c2ccc3c(=O)c(C(=O)O)cn(C4CC4)c3c2C)cc1C,0,0,0,0,0.6,0.4,hERG non-blocker,ozenoxacin,1,CNc1ncc(-c2ccc3c(=O)c(C(=O)O)cn(C4CC4)c3c2C)cc1C
palbociclib,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,0,1,0,1,0.7,0.7,hERG non-blocker,palbociclib,1,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O
panobinostat,Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,0,1,1,1,0.6,0.6,hERG blocker,panobinostat,1,Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1
paritaprevir,Cc1cnc(C(=O)NC2CCCCC/C=C\C3CC3(C(=O)NS(=O)(=O)C3CC3)NC(=O)C3CC(Oc4nc5ccccc5c5ccccc45)CN3C2=O)cn1,0,0,0,1,0.5,0.5,hERG non-blocker,paritaprevir,1,Cc1cnc(C(=O)NC2CCCCC/C=C\C3CC3(C(=O)NS(=O)(=O)C3CC3)NC(=O)C3CC(Oc4nc5ccccc5c5ccccc45)CN3C2=O)cn1
peramivir,CCC(CC)C(NC(C)=O)C1C(NC(=N)N)CC(C(=O)O)C1O,0,0,0,0,0.7,0.3,hERG non-blocker,peramivir,1,CCC(CC)C(NC(C)=O)C1C(NC(=N)N)CC(C(=O)O)C1O
perampanel,N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O,0,0,1,1,0.5,0.5,hERG blocker,perampanel,1,N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O
pibrentasvir,COC(=O)NC(C(=O)N1CCCC1c1nc2cc(C3CCC(c4cc5nc(C6CCCN6C(=O)C(NC(=O)OC)C(C)OC)[nH]c5cc4F)N3c3cc(F)c(N4CCC(c5ccc(F)cc5)CC4)c(F)c3)c(F)cc2[nH]1)C(C)OC,0,0,0,1,0.5,0.5,hERG non-blocker,pibrentasvir,1,COC(=O)NC(C(=O)N1CCCC1c1nc2cc(C3CCC(c4cc5nc(C6CCCN6C(=O)C(NC(=O)OC)C(C)OC)[nH]c5cc4F)N3c3cc(F)c(N4CCC(c5ccc(F)cc5)CC4)c(F)c3)c(F)cc2[nH]1)C(C)OC
pimavanserin,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,1,1,1,1,0.5,0.5,hERG blocker,pimavanserin,1,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1
pirfenidone,Cc1ccc(=O)n(-c2ccccc2)c1,0,0,0,0,0.5,0.5,hERG non-blocker,pirfenidone,1,Cc1ccc(=O)n(-c2ccccc2)c1
plazomicin,CNC1C(O)C(OC2C(NC(=O)C(O)CCN)CC(N)C(OC3OC(CNCCO)=CCC3N)C2O)OCC1(C)O,0,0,0,0,0.5,0.5,hERG non-blocker,plazomicin,1,CNC1C(O)C(OC2C(NC(=O)C(O)CCN)CC(N)C(OC3OC(CNCCO)=CCC3N)C2O)OCC1(C)O
pomalidomide,Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0,0,0,0,0.5,0.5,hERG non-blocker,pomalidomide,1,Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O
ponatinib,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,0,1,1,0,0.5,0.5,hERG blocker,ponatinib,1,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,0,0,0,0,0.7,0.3,hERG non-blocker,regorafenib,1,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
revefenacin,CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1,0,0,1,0,0.5,0.5,hERG blocker,revefenacin,1,CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1
ribociclib,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,0,1,0,1,0.5,0.5,hERG non-blocker,ribociclib,1,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1
riociguat,COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,0,0,0,0,0.6,0.4,hERG non-blocker,riociguat,1,COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N
rolapitant,CC(OCC1(c2ccccc2)CCC2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,1,1,1,1,0.6,0.6,hERG blocker,rolapitant,1,CC(OCC1(c2ccccc2)CCC2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
rucaparib,CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,0,0,1,1,0.6,0.6,hERG blocker,rucaparib,1,CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1
sacubitril,CCOC(=O)C(C)CC(Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,0,0,0,1,0.6,0.6,hERG non-blocker,sacubitril,1,CCOC(=O)C(C)CC(Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O
safinamide,CC(NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O,0,0,1,0,0.6,0.4,hERG blocker,safinamide,1,CC(NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O
sarecycline,CON(C)Cc1ccc(O)c2c1CC1CC3C(N(C)C)C(O)=C(C(N)=O)C(=O)C3(O)C(O)=C1C2=O,0,0,0,0,0.5,0.5,hERG non-blocker,sarecycline,1,CON(C)Cc1ccc(O)c2c1CC1CC3C(N(C)C)C(O)=C(C(N)=O)C(=O)C3(O)C(O)=C1C2=O
secnidazole,Cc1ncc([N+](=O)[O-])n1CC(C)O,0,0,0,0,0.8,0.2,hERG non-blocker,secnidazole,1,Cc1ncc([N+](=O)[O-])n1CC(C)O
segesterone acetate,C=C1CC2C3CCC4=CC(=O)CCC4C3CCC2(C)C1(OC(C)=O)C(C)=O,0,0,0,0,0.6,0.4,hERG non-blocker,segesterone acetate,1,C=C1CC2C3CCC4=CC(=O)CCC4C3CCC2(C)C1(OC(C)=O)C(C)=O
selexipag,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,0,0,1,0,0.5,0.5,hERG blocker,selexipag,1,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1
sofosbuvir,CC(C)OC(=O)C(C)NP(=O)(OCC1OC(n2ccc(=O)[nH]c2=O)C(C)(F)C1O)Oc1ccccc1,0,0,0,0,0.5,0.5,hERG non-blocker,sofosbuvir,1,CC(C)OC(=O)C(C)NP(=O)(OCC1OC(n2ccc(=O)[nH]c2=O)C(C)(F)C1O)Oc1ccccc1
sonidegib,Cc1c(C(=O)Nc2ccc(N3CC(C)OC(C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,0,0,1,0,0.6,0.4,hERG blocker,sonidegib,1,Cc1c(C(=O)Nc2ccc(N3CC(C)OC(C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1
sugammadex,O=C(O)CCSCC1OC2OC3C(CSCCC(=O)O)OC(OC4C(CSCCC(=O)O)OC(OC5C(CSCCC(=O)O)OC(OC6C(CSCCC(=O)O)OC(OC7C(CSCCC(=O)O)OC(OC8C(CSCCC(=O)O)OC(OC9C(CSCCC(=O)O)OC(OC1C(O)C2O)C(O)C9O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O,0,0,0,0,0.6,0.4,hERG non-blocker,sugammadex,1,O=C(O)CCSCC1OC2OC3C(CSCCC(=O)O)OC(OC4C(CSCCC(=O)O)OC(OC5C(CSCCC(=O)O)OC(OC6C(CSCCC(=O)O)OC(OC7C(CSCCC(=O)O)OC(OC8C(CSCCC(=O)O)OC(OC9C(CSCCC(=O)O)OC(OC1C(O)C2O)C(O)C9O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O
sulfur hexafluoride,FS(F)(F)(F)(F)F,0,0,0,1,0.6,0.6,hERG non-blocker,sulfur hexafluoride,1,FS(F)(F)(F)(F)F
suvorexant,Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CCC2C)c1,0,0,0,1,0.5,0.5,hERG non-blocker,suvorexant,1,Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CCC2C)c1
tafenoquine,COc1cc(C)c2c(Oc3cccc(C(F)(F)F)c3)c(OC)cc(NC(C)CCCN)c2n1,0,1,1,1,0.7,0.7,hERG blocker,tafenoquine,1,COc1cc(C)c2c(Oc3cccc(C(F)(F)F)c3)c(OC)cc(NC(C)CCCN)c2n1
tafluprost,CC(C)OC(=O)CCC/C=C\CC1C(O)CC(O)C1/C=C/C(F)(F)COc1ccccc1,0,0,0,1,0.5,0.5,hERG non-blocker,tafluprost,1,CC(C)OC(=O)CCC/C=C\CC1C(O)CC(O)C1/C=C/C(F)(F)COc1ccccc1
tasimelteon,CCC(=O)NCC1CC1c1cccc2c1CCO2,0,0,1,0,0.7,0.3,hERG blocker,tasimelteon,1,CCC(=O)NCC1CC1c1cccc2c1CCO2
tavaborole,OB1OCc2cc(F)ccc21,0,0,0,1,0.6,0.6,hERG non-blocker,tavaborole,1,OB1OCc2cc(F)ccc21
tecovirimat,O=C(NN1C(=O)C2C3C=CC(C4CC34)C2C1=O)c1ccc(C(F)(F)F)cc1,0,0,0,0,0.5,0.5,hERG non-blocker,tecovirimat,1,O=C(NN1C(=O)C2C3C=CC(C4CC34)C2C1=O)c1ccc(C(F)(F)F)cc1
telotristat ethyl,CCOC(=O)C(N)Cc1ccc(-c2cc(OC(c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1,1,1,1,1,0.6,0.6,hERG blocker,telotristat ethyl,1,CCOC(=O)C(N)Cc1ccc(-c2cc(OC(c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1
teriflunomide,C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,0,0,0,0,0.7,0.3,hERG non-blocker,teriflunomide,1,C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1
tezacaftor,CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1CC(O)CO,0,0,0,1,0.5,0.5,hERG non-blocker,tezacaftor,1,CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1CC(O)CO
tipiracil,N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl,0,0,0,1,0.6,0.6,hERG non-blocker,tipiracil,1,N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl
tofacitinib,CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12,0,0,0,0,0.7,0.3,hERG non-blocker,tofacitinib,1,CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12
trabectedin,COc1cc2c(cc1O)CCNC21CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4,0,0,0,0,0.5,0.5,hERG non-blocker,trabectedin,1,COc1cc2c(cc1O)CCNC21CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4
trametinib,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,0,1,0,1,0.5,0.5,hERG non-blocker,trametinib,1,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1
umeclidinium,OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2,0,1,1,1,0.5,0.5,hERG blocker,umeclidinium,1,OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2
uridine triacetate,CC(=O)OCC1OC(n2ccc(=O)[nH]c2=O)C(OC(C)=O)C1OC(C)=O,0,0,0,0,0.6,0.4,hERG non-blocker,uridine triacetate,1,CC(=O)OCC1OC(n2ccc(=O)[nH]c2=O)C(OC(C)=O)C1OC(C)=O
vaborbactam,O=C(O)CC1CCC(NC(=O)Cc2cccs2)B(O)O1,0,0,0,0,0.6,0.4,hERG non-blocker,vaborbactam,1,O=C(O)CC1CCC(NC(=O)Cc2cccs2)B(O)O1
valbenazine,COc1cc2c(cc1OC)C1CC(OC(=O)C(N)C(C)C)C(CC(C)C)CN1CC2,0,1,0,0,0.5,0.5,hERG non-blocker,valbenazine,1,COc1cc2c(cc1OC)C1CC(OC(=O)C(N)C(C)C)C(CC(C)C)CN1CC2
vilanterol,OCc1cc(C(O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,0,1,1,1,0.6,0.6,hERG blocker,vilanterol,1,OCc1cc(C(O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O
vismodegib,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,0,0,1,0,0.5,0.5,hERG blocker,vismodegib,1,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1
vorapaxar,CCOC(=O)NC1CCC2C(C1)CC1C(=O)OC(C)C1C2/C=C/c1ccc(-c2cccc(F)c2)cn1,0,0,1,0,0.5,0.5,hERG blocker,vorapaxar,1,CCOC(=O)NC1CCC2C(C1)CC1C(=O)OC(C)C1C2/C=C/c1ccc(-c2cccc(F)c2)cn1
vortioxetine,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,0,1,1,1,0.6,0.6,hERG blocker,vortioxetine,1,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1
